{"id":477021,"date":"2020-03-31T17:14:02","date_gmt":"2020-03-31T17:14:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=477021"},"modified":"2020-03-31T17:14:02","modified_gmt":"2020-03-31T17:14:02","slug":"cushings-syndrome-pipeline-analysis-companies-working-on-cushings-syndrome-competitive-landscape","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/cushings-syndrome-pipeline-analysis-companies-working-on-cushings-syndrome-competitive-landscape_477021.html","title":{"rendered":"Cushing’s Syndrome Pipeline Analysis, Companies working on Cushing’s Syndrome Competitive landscape"},"content":{"rendered":"
\"Cushing\\'s<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
“Cushing’s Syndrome Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Cushing’s Syndrome market. A detailed picture of the Cushing’s Syndrome pipeline landscape is provided, which includes the disease overview and Cushing’s Syndrome treatment guidelines. <\/div>\n

“Cushing’s Syndrome Pipeline Insight, 2020<\/a>” report by DelveInsight<\/strong> outlays comprehensive insights of present clinical development scenario and growth prospects across the Cushing’s Syndrome market. A detailed picture of the Cushing’s Syndrome pipeline landscape is provided, which includes the disease overview and Cushing’s Syndrome treatment guidelines.<\/p>\n

The assessment part of the report embraces in-depth Cushing’s Syndrome commercial assessment and clinical assessment of the Cushing’s Syndrome pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cushing’s Syndrome collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/p>\n

\"\"<\/strong><\/p>\n

Pipeline Development Activities:<\/strong>
The report provides insights into: 
1. All of the companies that are developing therapies for the treatment of Cushing’s Syndrome with aggregate therapies developed by each company for the same.
2. Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Cushing’s Syndrome treatment.
3. Cushing’s Syndrome key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
4. Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
5. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Cushing’s Syndrome market.<\/p>\n

The report is built using data and information traced from the researcher’s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university web sites and industry-specific third-party sources, etc.  <\/p>\n

“The endogenous Cushing’s Syndrome prevalence is 1\/26,000.”<\/strong><\/p>\n

Request for sample pages: <\/strong>https:\/\/www.delveinsight.com\/sample-request\/cushings-syndrome-pipeline-insight<\/p>\n

Scope of the report:<\/strong>
1. The Cushing’s Syndrome report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Cushing’s Syndrome across the complete product development cycle, including all clinical and nonclinical stages.
2. It comprises of detailed profiles of Cushing’s Syndrome therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
3. Detailed Cushing’s Syndrome research and development progress and trial details, results wherever available, are also included in the pipeline study.
4. Coverage of dormant and discontinued pipeline projects along with the reasons if available across Cushing’s Syndrome. <\/p>\n

Report highlights:<\/strong>
1. A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Cushing’s Syndrome.   
2. In the coming years, the Cushing’s Syndrome market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
3. The companies and academics that are working to assess challenges and seek opportunities that could influence Cushing’s Syndrome R&D. The therapies under development are focused on novel approaches to treat\/improve the disease condition.
4. A detailed portfolio of major pharma players who are involved in fueling the Cushing’s Syndrome treatment market. Several potential therapies for Cushing’s Syndrome are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Cushing’s Syndrome market size in the coming years. 
5. Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Cushing’s Syndrome) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities. <\/p>\n

The key pharma players in Cushing’s syndrome market are:<\/strong>
1. Recordati
2. Corcept Therapeutics
3. Strongbridge Biopharma
4. HRA Pharma
5. Millendo Therapeutics
And many others<\/p>\n

The launch of the emerging therapies is expected to significantly impact Cushing’s syndrome treatment scenario in the upcoming years: –<\/strong>
Drugs covered<\/strong>
1. Osilodrostat
2. Relacorilant
3. Levoketoconazole
4. Metyrapone
5. ATR-101
And many others<\/p>\n

Table of Contents:<\/strong>
1. Report Introduction
2. Cushing’s Syndrome
3. Cushing’s Syndrome Current Treatment Patterns
4. Cushing’s Syndrome – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Cushing’s Syndrome Late Stage Products (Phase-III)
7. Cushing’s Syndrome Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Cushing’s Syndrome Discontinued Products
13. Cushing’s Syndrome Product Profiles
14. Cushing’s Syndrome Key Companies
15. Cushing’s Syndrome Key Products
16. Dormant and Discontinued Products
17. Cushing’s Syndrome Unmet Needs
18. Cushing’s Syndrome Future Perspectives
19. Cushing’s Syndrome Analyst Review 
20. Appendix
21. Report Methodology<\/p>\n

Download full report:<\/strong> https:\/\/www.delveinsight.com\/sample-request\/cushings-syndrome-pipeline-insight<\/p>\n

Related reports:<\/strong><\/p>\n

Endogenous Cushing’s Syndrome – Epidemiology Forecast to 2030<\/a> <\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Kritika Rehani
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +919650213330
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Albany
State:<\/strong> New York
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight Business Research LLP “Cushing’s Syndrome Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Cushing’s Syndrome market. A detailed picture of the Cushing’s Syndrome pipeline landscape is provided, which … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-477021","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/477021","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=477021"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/477021\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=477021"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=477021"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=477021"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}